Answers are grounded in this paper and cite their sources.
Review shows an association between cardiovascular disease and poor prognosis in COVID-19, highlighting critical pharmacological management needs.
A highly pathogenic human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized in Wuhan, China, as the cause of the coronavirus disease 2019 (COVID-19) outbreak which has spread rapidly from China to other countries in the world, causing a pandemic with alarming morbidity and mortality. The emerging epidemiological data about COVID-19 patients suggest an association between cardiovascular diseases (CVD) and SARS-CoV-2 infection, in term of clinical features at hospital admission and prognosis for disease severity. The aim of our review is to describe the cardiological features of COVID-19 patients at admission, the acute cardiac presentation, the clinical outcome for patients with underlying CVD and the pharmacological implications for disease management.
No takes yet. Share an insight, caveat, or question.
Russo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: